搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
3 天
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
3 天
潜在首款!治疗特应性皮炎,安进单抗3期试验达双主要终点
特应性皮炎是最常见的湿疹类型,是一种慢性炎症性疾病,会导致皮肤过度干燥、瘙痒并伴有疼痛。中度至重度特应性皮炎患者会出现慢性症状,不可预测的发作会加剧症状,可能带来疼痛并扰乱日常生活。这些患者中几乎有一半报告出现严重瘙痒,导致反复抓挠,这会导致皮肤增厚 ...
4 天
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in ...
dermatologyadvisor
2 天
HORIZON: Rocatinlimab Effective in Adults With Atopic Dermatitis
Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.
1 天
Astria Therapeutics股票因OX40项目前景保持买入评级
周五,H.C. Wainwright维持对Astria Therapeutics (NASDAQ:ATXS)的买入评级,目标价格坚持在16.00美元。该公司的关注点集中在本周早些时候关于一种竞争性特应性皮炎(AD)治疗方法的最新进展上。安进公司宣布了其OX40抗体rocatinlimab在HORIZON试验中的初步第三期结果。 研究报告显示,rocatinlimab的表现优于安慰剂,达到了所有主要 ...
4 天
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data ...
In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...
STAT
4 天
Amgen scores late-stage trial success for eczema and myasthenia gravis treatments, but ...
Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...
新浪网
4 天
安进:OX40抗体特应性皮炎三期临床成功
2024年9月24日,安进公布自免/炎症领域最新临床进展,包括OX40抗体Rocatinlimab治疗特应性皮炎、CD19抗体Uplizna治疗IgG4相关疾病 ...
4 天
Amgen stock slips 3% following Phase 3 data for rocatinlimab, Uplizna (update)
Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...
4 天
BMO Capital维持Amgen股票"跑赢大市"评级
BMO Capital对Amgen (NASDAQ: AMGN)股票保持积极展望,重申"跑赢大市"评级,目标价维持在362.00美元。 该公司的分析强调了Amgen最近临床试验的喜忧参半结果。Amgen的rocatinlimab在特应性皮炎治疗中的III期HORIZON研究显示,在24周时EASI-75反应率达到32.8%,具有统计学显著性。
4 天
Hold Rating on Amgen Amid Concerns Over Rocatinlimab and Uplizna Trial Results
Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating today. David Risinger has ...
4 天
on MSN
Amgen’s stock falls 4% as analysts say drug updates lag competitors
The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈